Sales of antibiotics in Russian pharmacies in the first nine months of 2020 amounted to 28.6 billion roubles ($376 million), which is 14% higher compared to the same period of last year, according to a recent report prepared by the Russian analytics companies Pharmvestnik and AlphaRM.
According to the companies, in volume terms, sales grew by about 15% to 176.6 million packs, with the biggest growth being observed in the case of azithromycin, amoxicillin, amoxicillin + clavulanic acid, clarithromycin, levofloxacin and moxifloxacin.
The growth was registered in the case of antibiotics that are produced both by domestic and foreign pharmaceutical companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze